慢性自发性荨麻疹活动度相关生物学指标的研究进展

doi:10.35541/cjd.20201158

Abstract

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is a recurrent systemic inflammatory disease. At present, there are few biological indicators that can effectively reflect CSU activity in clinical practice, and some indicators have not been widely used. To identify sensitive and easy-to-check indicators may be helpful for the diagnosis and treatment of as well as prediction of therapeutic efficacy in CSU. This review comprehensively summarizes current clinical application of indicators related to CSU activity, in order to provide a reference for clinical practice and related scientific research.

Key words: Urticaria, Chronic spontaneous urticaria, Disease activity, Biological indicators

Jiao Qingqing, Zhang Xiaoyan, Ji Jiang. Biological indicators related to disease activity of chronic spontaneous urticaria: an update[J]. Chinese Journal of Dermatology, 2023, 56(6): 559-562.doi:10.35541/cjd.20201158

References ［34］

［1］	Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria［J］. Allergy, 2018,73（7）:1393⁃1414. doi: 10.1111/all.13397.
［2］	Saini SS, Kaplan AP. Chronic spontaneous urticaria: the Devil′s itch［J］. J Allergy Clin Immunol Pract, 2018,6（4）:1097⁃1106. doi: 10.1016/j.jaip.2018.04.013.
［3］	Marsland AM. Autoimmunity and complement in the pathogenesis of chronic urticaria［J］. Curr Allergy Asthma Rep, 2006,6（4）:265⁃269. doi: 10.1007/s11882⁃006⁃0058⁃8.
［4］	Pałgan K, Bartuzi Z. Platelet activating factor in allergies［J］. Int J Immunopathol Pharmacol, 2015,28（4）:584⁃589. doi: 10.1177/0394632015600598.
［5］	Yanase Y, Takahagi S, Hide M. Chronic spontaneous urticaria and the extrinsic coagulation system ［J］. AllergolInt, 2018,67（2）:191⁃194. doi: 10.1016/j.alit.2017.09.003.
［6］	Jain S. Pathogenesis of chronic urticaria: an overview［J］. Dermatol Res Pract, 2014,2014:674709. doi: 10.1155/2014/674709.
［7］	Tedeschi A, Kolkhir P, Asero R, et al. Chronic urticaria and coagulation: pathophysiological and clinical aspects［J］. Allergy, 2014,69（6）:683⁃691. doi: 10.1111/all.12389.
［8］	Ulambayar B, Yang EM, Cha HY, et al. Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study［J］. Clin Transl Allergy, 2019,9:33. doi: 10.1186/s13601⁃019⁃0275⁃6.
［9］	Vadas P, Perelman B, Liss G. Platelet⁃activating factor, histamine, and tryptase levels in human anaphylaxis［J］. J Allergy Clin Immunol, 2013,131（1）:144⁃149. doi: 10.1016/j.jaci.2012.08.016.
［10］	Aleem S, Masood Q, Hassan I. Correlation of mean platelet volume levels with severity of chronic urticaria［J］. Indian J Dermatol, 2014,59（6）:636. doi: 10.4103/0019⁃5154.143607.
［11］	Hide M, Suzuki T, Tanaka A, et al. Long⁃term safety and efficacy of rupatadine in Japanese patients with itching due to chronic spontaneous urticaria, dermatitis, or pruritus: a 12⁃month, multicenter, open⁃label clinical trial［J］. J Dermatol Sci, 2019,94（3）:339⁃345. doi: 10.1016/j.jdermsci.2019.05.008.
［12］	Hong GU, Park BS, Park JW,et al. IgE production in CD40/CD40L cross⁃talk of B and mast cells and mediator release via TGase 2 in mouse allergic asthma［J］. Cell Signal, 2013,25（6）:1514⁃1525. doi: 10.1016/j.cellsig.2013.03.010.
［13］	Bae Y, Kang SH, Park JO, et al. Serum transglutaminase 2 activity as a potential biomarker of disease severity and response to omalizumab in chronic spontaneous urticaria［J］. Allergol Int, 2020,69（2）:304⁃306. doi: 10.1016/j.alit.2019.10.009.
［14］	Johnson ED, Schell JC, Rodgers GM. The D⁃dimer assay［J］. Am J Hematol, 2019,94（7）:833⁃839. doi: 10.1002/ajh.25482.
［15］	Vadasz Z, Toubi E. Hemostasis in allergy［J］. Semin Thromb Hemost, 2018,44（7）:669⁃675. doi: 10.1055/s⁃0038⁃1648232.
［16］	Triwongwaranat D, Kulthanan K, Chularojanamontri L, et al. Correlation between plasma D⁃dimer levels and the severity of patients with chronic urticaria［J］. Asia Pac Allergy, 2013,3（2）:100⁃105. doi: 10.5415/apallergy.2013.3.2.100.
［17］	Asero R. Are currently available biomarkers useful to discriminate CSU patients not controlled by low dose omalizumab maintenance therapy?［J］. Eur Ann Allergy Clin Immunol, 2020,52（6）:268⁃270. doi: 10.23822/EurAnnACI.1764⁃1489.139.
［18］	de Montjoye L, Darrigade AS, Giménez⁃Arnau A, et al. Correlations between disease activity, autoimmunity and biological parameters in patients with chronic spontaneous urticaria［J］. Eur Ann Allergy Clin Immunol, 2021,53（2）:55⁃66. doi: 10.23822/EurAnnACI.1764⁃1489.132.
［19］	Varghese R, Rajappa M, Chandrashekar L, et al. Association among stress, hypocortisolism, systemic inflammation, and disease severity in chronic urticaria［J］. Ann Allergy Asthma Immunol, 2016,116（4）:344⁃348. doi: 10.1016/j.anai.2016.01. 016.
［20］	Trinh HK, Pham DL, Ban GY, et al. Altered systemic adipokines in patients with chronic urticaria［J］. Int Arch Allergy Immunol, 2016,171（2）:102⁃110. doi: 10.1159/000452626.
［21］	Zwicky P, Unger S, Becher B. Targeting interleukin⁃17 in chronic inflammatory disease: a clinical perspective［J］. J Exp Med, 2020,217（1）:e20191123. doi: 10.1084/jem.20191123.
［22］	Teng MW, Bowman EP, McElwee JJ, et al. IL⁃12 and IL⁃23 cytokines: from discovery to targeted therapies for immune⁃mediated inflammatory diseases［J］. Nat Med, 2015,21（7）:719⁃729. doi: 10.1038/nm.3895.
［23］	Sharma P, Sharma PK, Chitkara A, et al. To evaluate the role and relevance of cytokines IL⁃17, IL⁃18, IL⁃23 and TNF⁃α and their correlation with disease severity in chronic urticaria［J］. Indian Dermatol Online J, 2020,11（4）:594⁃597. doi: 10.4103/idoj.IDOJ_396_19.
［24］	Shoda T, Futamura K, Orihara K, et al. Recent advances in understanding the roles of vascular endothelial cells in allergic inflammation［J］. Allergol Int, 2016,65（1）:21⁃29. doi: 10.1016/j.alit.2015.08.001.
［25］	Zhang L, Qi R, Yang Y, et al. Serum miR⁃125a⁃5p and CCL17 upregulated in chronic spontaneous urticaria and correlated with treatment response［J］. Acta Derm Venereol, 2019,99（6）:571⁃578. doi: 10.2340/00015555⁃3149.
［26］	Metz M, Krull C, Maurer M. Histamine, TNF, C5a, IL⁃6, ⁃9, ⁃18, ⁃31, ⁃33, TSLP, neopterin, and VEGF are not elevated in chronic spontaneous urticaria［J］. J Dermatol Sci, 2013,70（3）:222⁃225. doi: 10.1016/j.jdermsci.2013.03.003.
［27］	Elieh Ali Komi D, Shafaghat F, Kovanen PT, et al. Mast cells and complement system: ancient interactions between components of innate immunity［J］. Allergy, 2020,75（11）:2818⁃2828. doi: 10.1111/all.14413.
［28］	Kasperska⁃Zajac A, Grzanka A, Machura E, et al. Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration［J］. J Inflamm （Lond）, 2013,10（1）:22. doi: 10. 1186/1476⁃9255⁃10⁃22.
［29］	Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium internationale allergologicum （CIA） update 2020［J］. Int Arch Allergy Immunol, 2020,181（5）:321⁃333. doi: 10.1159/000507 218.
［30］	Türk M, Yılmaz İ, Bahçecioğlu SN. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty⁃five patients［J］. Allergol Int, 2018,67（1）:85⁃89. doi: 10.1016/j.alit.2017.05.003.
［31］	Ertas R, Ozyurt K, Ozlu E, et al. Increased IgE levels are linked to faster relapse in patients with omalizumab⁃discontinued chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2017,140（6）:1749⁃1751. doi: 10.1016/j.jaci.2017.08.007.
［32］	Kessel A, Helou W, Bamberger E, et al, Elevated serum total IgE⁃⁃a potential marker for severe chronic urticaria［J］. Int Arch Allergy Immunol, 2010,153（3）:288⁃293. doi: 10.1159/000314370.
［33］	Chanprapaph K, Iamsumang W, Wattanakrai P, et al. Thyroid autoimmunity and autoimmunity in chronic spontaneous urticaria linked to disease severity, therapeutic response, and time to remission in patients with chronic spontaneous urticaria［J］. Biomed Res Int, 2018,2018:9856843. doi: 10.1155/ 2018/9856843.
［34］	Curto⁃Barredo L, Yelamos J, Gimeno R, et al. Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease［J］. Immun Inflamm Dis, 2016,4（4）:441⁃445. doi: 10.1002/iid3.125.

[1]	Chen Qiquan, Yang Xianjie, Wang Wenwen, Liang Gaopeng, Song Zhiqiang . Development and application of clinical assessment tools for cholinergic urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 563-566.
[2]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[3]	Zhang Liming, Xiao Ting. Update of the autoimmune pathogenesis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 567-570.
[4]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[5]	Chen Qiquan, Kong Minmin, Yang Xianjie, Wang Huan, Li Jian, Zhang Mingwang, Song Zhiqiang. Clinical analysis of allergen reactivity and atopic disease history in 168 patients with chronic inducible urticaria [J]. Chinese Journal of Dermatology, 2023, 56(6): 496-503.
[6]	Su Chang, Sui Xiuli, Liu Ruiling, Cao Yiqun, Jiang Hong, Yan Cairong, Wang Huiping, Qi Yuqing. Omalizumab for the treatment of 74 patients with chronic spontaneous urticaria accompanied by other allergic diseases: a clinical analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 512-517.
[7]	Wang Xin, Liu Lijuan, Li Linfeng. Clinical features of chronic spontaneous urticaria in China: results from a hospital-based multicenter epidemiological survey [J]. Chinese Journal of Dermatology, 2023, 56(6): 525-530.
[8]	Li Liqiao, Peng Cong, Chen Xiang, Li Jie. Efficacy of omalizumab in the treatment of chronic urticaria patients with poor response to antihistamines: a single-center retrospective study [J]. Chinese Journal of Dermatology, 2023, 56(6): 504-511.
[9]	Chen Qiquan, Yang Xianjie, Gu Heng, Xu Jinhua, Hao Fei, Yao Xu, Song Zhiqiang. Construction of “Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023）” based on the Delphi method [J]. Chinese Journal of Dermatology, 2023, 56(6): 534-539.
[10]	Immunology Group, Chinese Society of Dermatology. Expert consensus on diagnosis and treatment of chronic inducible urticaria in China （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 479-488.
[11]	Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023） [J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.
[12]	Yang Xiaojing, Chen Leigang, Wang Shining, Wu Yuanhui, Zhu Youjin, An Guozhi, Zhou Xiangzhao, Meng Zhaoying. Correlation of serum interleukin-9 and platelet-activating factor levels with total IgE levels, disease severity and disease course in patients with chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(4): 337-341.
[13]	. Correlation between food-specific IgG antibodies and phenotypes of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(2): 130-135.
[14]	Yu Miao, Song Xiaoting, Liu Bo, Liao Shuanglu, Luan Tingting, Zhao Zuotao. Autologous serum skin test: immunological mechanisms and its associations with clinical features and prognosis of chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(2): 184-187.
[15]	Zhao Ying, Zhang Xiaoyan, Chen Lu, Su Yuhua, Ding Yujie, Leng Hong, Ji Jiang. Predictive factors for the efficacy of omalizumab in the treatment of refractory chronic spontaneous urticaria [J]. Chinese Journal of Dermatology, 2023, 56(1): 22-28.

Biological indicators related to disease activity of chronic spontaneous urticaria: an update

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［34］

Related Articles 15

Metrics

Comments

Recommended 10